SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo.
Saved in:
| Title: | SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo. |
|---|---|
| Authors: | Arosa L; Molecular and Cellular Gastroenterology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain., Malvar-Fernández B; Rheumatology & Immuno-mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain.; Rheumatology Department, University Hospital of Vigo, Vigo, Spain., Antúnez-López J; Department of Pathology, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain., García S; Rheumatology & Immuno-mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain.; Rheumatology Department, University Hospital of Vigo, Vigo, Spain., Conde-Aranda J; Molecular and Cellular Gastroenterology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Feb 04; Vol. 17, pp. 1677130. Date of Electronic Publication: 2026 Feb 04 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1677130 |
